123 related articles for article (PubMed ID: 10806834)
1. Effect of aprotinin on the red cell immunity in cardiopulmonary bypass.
Luo J; Huang Y; Lan H
J Tongji Med Univ; 1998; 18(2):97-100. PubMed ID: 10806834
[TBL] [Abstract][Full Text] [Related]
2. Effects of aprotinin on serum interleukin-2 and soluble interleukin-2 receptor during cardiopulmonary bypass.
Luo J; Wang D; Lan H; Sun Z
J Tongji Med Univ; 2000; 20(2):143-4. PubMed ID: 12845731
[TBL] [Abstract][Full Text] [Related]
3. Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response.
Koster A; Huebler S; Merkle F; Hentschel T; Gründel M; Krabatsch T; Tambeur L; Praus M; Habazettl H; Kuebler WM; Kuppe H
Anesth Analg; 2004 Feb; 98(2):285-290. PubMed ID: 14742356
[TBL] [Abstract][Full Text] [Related]
4. Effects of methylprednisolone and aprotinin on phospholipase D activity of leukocytes in systemic inflammatory response induced by cardiopulmonary bypass.
Wu M; Lu YB; Jiang B; Xu SW; Chen RK; Zhou HL
Acta Pharmacol Sin; 2001 Oct; 22(10):913-7. PubMed ID: 11749774
[TBL] [Abstract][Full Text] [Related]
5. [Randomized controlled trial for the effect of amrinone and aprotinin on proinflammatory cytokine release in patients with prosthetic valve replacement during perioperative period].
Xiao X; Luo C; Zhuang X; Yin D; Chen Y; Cao G; Huang X; Tian Z; Shi Y
Hua Xi Yi Ke Da Xue Xue Bao; 2001 Jun; 32(2):291-3. PubMed ID: 12600112
[TBL] [Abstract][Full Text] [Related]
6. Use of aprotinin during cardiopulmonary bypass in a patient with protein C deficiency.
Sievert A; McCall M; Blackwell M; Bradley S
J Extra Corpor Technol; 2003 Mar; 35(1):39-43. PubMed ID: 12680495
[TBL] [Abstract][Full Text] [Related]
7. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets.
Orchard MA; Goodchild CS; Prentice CR; Davies JA; Benoit SE; Creighton-Kemsford LJ; Gaffney PJ; Michelson AD
Br J Haematol; 1993 Nov; 85(3):533-41. PubMed ID: 7510990
[TBL] [Abstract][Full Text] [Related]
8. [Effects of blood washing and autotransfusion during cardiopulmonary bypass on erythrocyte immune and kidney function].
Song Y; Li R; Gu XH; Gong XJ; Zhang G; Wu SM; Zhang XQ; Li SX
Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(32):2293-6. PubMed ID: 17064580
[TBL] [Abstract][Full Text] [Related]
9. Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery.
Rocha E; Hidalgo F; Llorens R; Melero JM; Arroyo JL; Páramo JA
Circulation; 1994 Aug; 90(2):921-7. PubMed ID: 7519132
[TBL] [Abstract][Full Text] [Related]
10. Platelet protection by low-dose aprotinin in cardiopulmonary bypass: electron microscopic study.
Lavee J; Raviv Z; Smolinsky A; Savion N; Varon D; Goor DA; Mohr R
Ann Thorac Surg; 1993 Jan; 55(1):114-9. PubMed ID: 7678061
[TBL] [Abstract][Full Text] [Related]
11. Postoperatively administered aprotinin or epsilon aminocaproic acid after cardiopulmonary bypass has limited benefit.
Ray MJ; Hales MM; Brown L; O'Brien MF; Stafford EG
Ann Thorac Surg; 2001 Aug; 72(2):521-6. PubMed ID: 11515892
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of aprotinin against lung damage in patients undergoing CABG surgery.
Erdogan M; Kalaycioglu S; Iriz E
Acta Cardiol; 2005 Aug; 60(4):367-72. PubMed ID: 16128368
[TBL] [Abstract][Full Text] [Related]
13. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass.
Blauhut B; Gross C; Necek S; Doran JE; Späth P; Lundsgaard-Hansen P
J Thorac Cardiovasc Surg; 1991 Jun; 101(6):958-67. PubMed ID: 1710008
[TBL] [Abstract][Full Text] [Related]
14. "Low-dose" aprotinin modifies hemostasis but not proinflammatory cytokine release.
Ashraf S; Tian Y; Cowan D; Nair U; Chatrath R; Saunders NR; Watterson KG; Martin PG
Ann Thorac Surg; 1997 Jan; 63(1):68-73. PubMed ID: 8993243
[TBL] [Abstract][Full Text] [Related]
15. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R
Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
[TBL] [Abstract][Full Text] [Related]
16. Effect of aprotinin on plasma fibronectin levels during cardiopulmonary bypass.
al Khudhairi DM; Nadeem F; Zuleika AM; Hussain A; Ahmed A; el Sharkawy M
Ann Thorac Surg; 1997 Jan; 63(1):64-7. PubMed ID: 8993242
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of a cell saver and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing valve surgery.
Tempe DK; Banerjee A; Virmani S; Mehta N; Panwar S; Tomar AS; Ghambeer DK; Nigam M
J Cardiothorac Vasc Anesth; 2001 Jun; 15(3):326-30. PubMed ID: 11426363
[TBL] [Abstract][Full Text] [Related]
18. Reduction of blood activation in patients receiving aprotinin during cardiopulmonary bypass for coronary artery surgery.
Baufreton C; Velthuis HT; Jansen PG; Besnerais PL; Wildevuur CH; Loisance DY
ASAIO J; 1996; 42(5):M417-23. PubMed ID: 8944919
[TBL] [Abstract][Full Text] [Related]
19. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass.
Kawasuji M; Ueyama K; Sakakibara N; Tedoriya T; Matsunaga Y; Misaki T; Watanabe Y
Ann Thorac Surg; 1993 May; 55(5):1205-9. PubMed ID: 7684219
[TBL] [Abstract][Full Text] [Related]
20. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy.
Lu H; Du Buit C; Soria J; Touchot B; Chollet B; Commin PL; Conseiller C; Echter E; Soria C
Thromb Haemost; 1994 Sep; 72(3):438-43. PubMed ID: 7531877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
